Robert A. Verhagen
Director/Board Member at ImmunoBiochem Corp.
Profile
Robert A.
Verhagen is currently a Director at ImmunoBiochem Corp.
Previously, he was the President, Chief Executive Officer & Director at Helix BioPharma Corp.
from 2012 to 2015.
He also held the position of Vice President-Business Development at Spectral Medical, Inc. Verhagen obtained his undergraduate degree and MBA from the University of Alberta.
Robert A. Verhagen active positions
Companies | Position | Start |
---|---|---|
ImmunoBiochem Corp.
ImmunoBiochem Corp. BiotechnologyHealth Technology ImmunoBiochem Corp. is a biopharmaceutical company founded in 2007, based in Canada. The private company is focused on developing biological therapeutics to address unmet needs in oncology and immuno-oncology. ImmunoBiochem has worked closely with the University of Toronto, one of the world's leading institutions in research and innovation, on some of its novel programs. The Canadian company uses high-throughput functional screens, bioinformatics, and AI/ML to discover novel tumor targets in the tumor microenvironment, particularly in the cancer cell secretome. The company is a Johnson & Johnson Innovation JLABS alumnus and is headquartered in the heart of Canada's largest biomedical research hub. | Director/Board Member | - |
Former positions of Robert A. Verhagen
Companies | Position | End |
---|---|---|
HELIX BIOPHARMA CORP. | Chief Executive Officer | 31/10/2015 |
SPECTRAL MEDICAL INC. | Corporate Officer/Principal | - |
Training of Robert A. Verhagen
University of Alberta | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SPECTRAL MEDICAL INC. | Health Technology |
HELIX BIOPHARMA CORP. | Health Technology |
Private companies | 1 |
---|---|
ImmunoBiochem Corp.
ImmunoBiochem Corp. BiotechnologyHealth Technology ImmunoBiochem Corp. is a biopharmaceutical company founded in 2007, based in Canada. The private company is focused on developing biological therapeutics to address unmet needs in oncology and immuno-oncology. ImmunoBiochem has worked closely with the University of Toronto, one of the world's leading institutions in research and innovation, on some of its novel programs. The Canadian company uses high-throughput functional screens, bioinformatics, and AI/ML to discover novel tumor targets in the tumor microenvironment, particularly in the cancer cell secretome. The company is a Johnson & Johnson Innovation JLABS alumnus and is headquartered in the heart of Canada's largest biomedical research hub. | Health Technology |
- Stock Market
- Insiders
- Robert A. Verhagen